海盐造“救命核药”获批

动脉网
Nov 25, 2025

嘉兴日报讯,国家药监局批准诺华旗下派威妥^®特昔维匹肽注射液上市,该药是我国首个获批的PSMA靶向放射配体疗法药物,被誉为精准打击前列腺癌的“生物导弹”,从申请到获批仅用时约一年,填补了晚期前列腺癌治疗临床空白。其原理是将放射性核素镥-177与靶向PSMA的配体结合,精准打击肿瘤且减少对健康组织损伤。此前,核药临床应用受供应效率瓶颈制约,镥-177半衰期短,进口药常因运输延误失效。2024年底秦山...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10